Hawthorne, New Jersey Clinical Trials

A listing of Hawthorne, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

This is a global, Phase 1/2, multicenter, open-label study. The clinical study will include of Phase 1: Dose Escalation (non-randomized, dose finding study) and Phase 2: Dose Expansion (randomized efficacy exploration). For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 …

ccnu
systemic therapy
renal function
gilbert's syndrome
recurrent disease
Hackensack Meridian Health, 92 Second Street
 (7.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence). Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) …

serum bilirubin level
anticoagulants
primary cns lymphoma
aptt
ct scan
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
 (8.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

haemophilia a
bethesda assay
hemophilia
antihemophilic factor
fitusiran
Investigational Site Number 8400008
 (7.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

proteasome inhibitor
lenalidomide
measurable disease
corticosteroids
parenteral administration
Investigational Site Number 8400006
 (7.4 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

haemophilia a
bethesda assay
hemophilia
antihemophilic factor
fitusiran
Investigational Site Number 8400008
 (7.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

olaparib
paclitaxel
carboplatin
recurrent disease
cancer
Research Site
 (4.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +94 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

paclitaxel
kaposi sarcoma
non-small cell carcinoma
carboplatin
stage iia lung cancer ajcc v7
Neurosurgeons of New Jersey-Ridgewood
 (3.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +358 other locations
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.

systemic therapy
measurable disease
solid tumour
metastasis
oophorectomy
John Theurer Cancer Center at Hackensack University Medical Center
 (7.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for …

Memorial Sloan Kettering Bergen (Limited Protocol Activities)
 (8.8 away) Contact site
  • 0 views
  • 02 Dec, 2024
  • +6 other locations
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by …

high-dose chemotherapy
acupuncture
opioid use
pain management
opioid
Hackensack Meridian Health
 (7.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations